The potential role of dendritic cells in the therapy of Type 1 diabetes
- Details
- Publication Year 2013-06,Volume 5,Issue #6,Page 591-606
- Journal Title
- IMMUNOTHERAPY
- Publication Type
- Journal Article
- Abstract
- Type 1 diabetes (T1D) is the result of T-cell mediated autoimmune destruction of pancreatic islet beta-cells. The two current treatments for T1D are based on insulin or islet-cell replacement rather than the pathogenesis of T1D and remain problematic. Islet/pancreas transplantation does not cater for the majority of sufferers due to the lack of supply of organs and the need for continuous immunosuppression regimens. The mainstay treatment is insulin replacement, but this is disruptive to lifestyle and does not protect against severe long-term complications. An early vaccination and long-term restoration of immune tolerance to self-antigens in T1D patients (reversing the immunopathogenesis of the disease) would be preferable. Dendritic cells (DCs) are potent APCs and play an important role in inducing and maintaining immune tolerance. Targeting DCs through different DC surface molecules shows effective modulation of immune responses. Their feasibility for immunotherapy to prolong transplant survival and cancer immunotherapy has been demonstrated. Therefore, DCs could potentially be used in the treatment of autoimmune diseases. This review summarizes new insights into DCs as a potential therapeutic target for the treatment of T1D.
- Publisher
- FUTURE MEDICINE LTD
- Keywords
- REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GLUTAMIC-ACID DECARBOXYLASE; C-TYPE LECTIN; COMPLETE FREUND ADJUVANT; GENOME-WIDE ASSOCIATION; TOLERANCE IN-VIVO; NOD MICE; AUTOIMMUNE-DISEASE; INTERFERON-ALPHA
- Research Division(s)
- Immunology
- Publisher's Version
- https://doi.org/10.2217/IMT.13.48
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2013-06-01 12:00:00